prikaz prve stranice dokumenta Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer's disease early detection and differential diagnosis in patients with mild cognitive impairment
  Preuzmi
PDF 1.05 MB
Znanstveni rad - Izvorni znanstveni rad
Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer's disease early detection and differential diagnosis in patients with mild cognitive impairment
Journal of Alzheimer's Disease, 50 (2016), 3; 765-778. https://doi.org/10.3233/JAD-150705
Babić Leko, Mirjana; Borovečki, Fran; Dejanović, Nenad; Hof, Patrick R.; Šimić, Goran

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Babić Leko, M., Borovečki, F., Dejanović, N., Hof, P. R. i Šimić, G. (2016). Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer's disease early detection and differential diagnosis in patients with mild cognitive impairment. Journal of Alzheimer's Disease, 50. (3), 765-778. doi: 10.3233/JAD-150705

Babić Leko, Mirjana, et al. "Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer's disease early detection and differential diagnosis in patients with mild cognitive impairment." Journal of Alzheimer's Disease, vol. 50, br. 3, 2016, str. 765-778. https://doi.org/10.3233/JAD-150705

Babić Leko, Mirjana, Fran Borovečki, Nenad Dejanović, Patrick R. Hof i Goran Šimić. "Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer's disease early detection and differential diagnosis in patients with mild cognitive impairment." Journal of Alzheimer's Disease 50, br. 3 (2016): 765-778. https://doi.org/10.3233/JAD-150705

Babić Leko, M., et al. (2016) 'Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer's disease early detection and differential diagnosis in patients with mild cognitive impairment', Journal of Alzheimer's Disease, 50(3), str. 765-778. doi: 10.3233/JAD-150705

Babić Leko M, Borovečki F, Dejanović N, Hof PR, Šimić G. Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer's disease early detection and differential diagnosis in patients with mild cognitive impairment. Journal of Alzheimer's Disease [Internet]. 2016. [pristupljeno 28.04.2024.];50(3):765-778. doi: 10.3233/JAD-150705

M. Babić Leko, F. Borovečki, N. Dejanović, P. R. Hof i G. Šimić, "Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer's disease early detection and differential diagnosis in patients with mild cognitive impairment", Journal of Alzheimer's Disease, vol. 50, br. 3, str. 765-778, 2016. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:599312. [Citirano: 28.04.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:599312
Podaci o radu
Naslov (engleski)Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer's disease early detection and differential diagnosis in patients with mild cognitive impairment
AutorMirjana Babić Leko
AutorFran Borovečki
AutorNenad Dejanović
AutorPatrick R. Hof
AutorGoran Šimić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Sažetak (engleski)
Visinin-like protein 1 (VILIP-1) recently emerged as a potential biomarker of Alzheimer's disease (AD). This neuronal calcium sensor protein previously used as a marker of acute ischemic stroke is elevated in the cerebrospinal fluid (CSF) of AD patients. The goal of this study was to assess CSF VILIP-1 potential in early AD diagnosis and in differentiating mild cognitive impairment (MCI) patients with and without risk of AD. Additionally, we tested VILIP-1 ability to differentiate AD from other primary causes of dementia, and predict the progression of AD-related cognitive decline. VILIP-1 levels were compared with five CSF AD biomarkers (t-tau, Aβ1-42, p-tau181, p-tau199, and p-tau231). VILIP-1 successfully differentiated two MCI patient groups characterized by absence or presence of pathological levels of these CSF biomarkers, except for t-tau. VILIP-1/Aβ(1-42) and VILIP-1/p-tau181 ratios also differentiated MCI patients with pathological CSF biomarker levels. However, there was no difference in VILIP-1 levels between AD and MCI patients. VILIP-1/Aβ(1-42) and VILIP-1/p-tau231 ratios reached high sensitivities (above 70%) and very high specificities (above 85%) in differentiating AD patients from HC. Additionally, VILIP-1 differentiated AD from patients with Lewy body disease with 77.1% sensitivity and 100% specificity. VILIP-1 potential as a prognostic biomarker of cognitive decline in AD was also proved since VILIP-1/t-tau, VILIP-1/p-tau181, and VILIP-1/p-tau231 ratios correlated with MMSE scores. These data indicate that VILIP-1 alone or in combination with other AD CSF biomarkers represent a valuable marker for the early diagnosis of AD, recognition of MCI patients at higher risk to develop dementia, and in differentiating AD from LBD.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaJournal of Alzheimer's Disease
Brojčani podacivol. 50, br. 3, str. 765-778
p-ISSN1387-2877
DOIhttps://doi.org/10.3233/JAD-150705
URN:NBNurn:nbn:hr:105:599312
Datum objave publikacije2016
URL dokumentahttps://doi.org/10.3233/JAD-150705
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 08:53:11